NASDAQ:TECH

Bio-Techne Stock Forecast, Price & News

$367.10

-10.12 (-2.68%)

(As of 01/21/2022 12:00 AM ET)

Add

Compare

Today's Range: $366.56
▼
$379.68
50-Day Range: $367.10
▼
$517.34
52-Week Range: $311.03
▼
$543.85

Volume: 399,498 shs
Average Volume: 293,849 shs
Market Capitalization: $14.43 billion

P/E Ratio: 84.78
Dividend Yield: 0.34%
Beta: 1.15

30 days | 90 days | 365 days | Advanced Chart

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

About Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The co

The total return for Bio-Techne (NASDAQ:TECH) investors has risen faster than earnings growth over the last five years
January 20, 2022 | finance.yahoo.com

Global COVID-19 EIA/ELISA Medical Devices Pipeline Landscape Report 2021: Product Description, Licensing and Collaboration Details and Other Developmental Activities - Yahoo Finance
January 20, 2022 | finance.yahoo.com

BIO-TECHNE ANNOUNCES COMMERCIAL RELEASE OF HIGH SENSITIVITY FLUORESCENT DETECTION STELLAR NIR / IR™ MODULES FOR JESS AUTOMATED WESTERN BLOTTING SYSTEM - Yahoo Finance
January 19, 2022 | finance.yahoo.com

Research Antibodies and Reagents Market Worth $6.32 billion - GlobeNewswire
January 18, 2022 | globenewswire.com

BIO-TECHNE ANNOUNCES COMMERCIAL RELEASE OF HIGH SENSITIVITY FLUORESCENT DETECTION STELLAR NIR / IR™ MODULES FOR JESS AUTOMATED WESTERN BLOTTING SYSTEM
January 18, 2022 | finance.yahoo.com

BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2022 TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS
January 17, 2022 | finance.yahoo.com

Thursday Sector Laggards: Technology & Communications, Healthcare - Nasdaq
January 13, 2022 | nasdaq.com

Global Spatial OMICS Market Size Estimated to Reach USD 484.29 Million By 2028: Polaris Market Research - Yahoo Finance
January 11, 2022 | finance.yahoo.com

Which Stocks To Buy Now? 4 Biotech Stocks To Know - Nasdaq
January 7, 2022 | nasdaq.com

BIO-TECHNE ANNOUNCES UPDATED PRESENTATION TIME AT THE J.P. MORGAN HEALTHCARE CONFERENCE
January 7, 2022 | finance.yahoo.com

Bio-Techne and Akoya Biosciences Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed and Resolution - Yahoo Finance
January 6, 2022 | finance.yahoo.com

The Global Exosome Diagnostics and Therapeutics Market is expected to grow by $ 419.37 mn during 2022-2026, progressing at a CAGR of 23.49% during the forecast period - Yahoo Finance
January 5, 2022 | finance.yahoo.com

Tesla and Moderna Started 2022 Differently—What History Says Happens Next - Barron's
January 4, 2022 | barrons.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Life Sciences Tools & Services
Sector: Medical
Current Symbol: NASDAQ:TECH
Previous Symbol
CUSIP: 87837710
CIK: 842023
Web: www.bio-techne.com
Phone: (612) 379-8854
Fax: 612-656-4400
Employees: 2,600
Year Founded: 1981

Sales & Book Value

Annual Sales: $931.03 million
Price / Sales: 15.49
Cash Flow: $7.73 per share
Price / Cash Flow: 47.48
Book Value: $40.40 per share
Price / Book: 9.09

Profitability

EPS (Most Recent Fiscal Year): $4.33
Net Income: $140.41 million
Net Margins: 17.94%
Pretax Margin: 17.90%
Return on Equity: 15.86%
Return on Assets: 11.50%

Debt

Debt-to-Equity Ratio: 0.17
Current Ratio: 4.06
Quick Ratio: 3.18

Price-To-Earnings

Trailing P/E Ratio: 84.78
Forward P/E Ratio: 53.67
P/E Growth: 2.72

Miscellaneous

Outstanding Shares: 39,295,000
Free Float: 37,684,000
Market Cap: $14.43 billion
Optionable: Optionable

Company Calendar

Last Earnings: 11/01/2021
Ex-Dividend for 11/26 Dividend: 11/10/2021
Dividend Payable: 11/26/2021
Today: 1/23/2022
Next Earnings (Confirmed): 2/01/2022
Fiscal Year End: 6/30/2022

Social Links

MarketRank^™

Overall MarketRank^™

2.75 out of 5 stars

Medical Sector

55th out of 1,419 stocks

Biological Products, Except Diagnostic Industry

7th out of 206 stocks

3.4 Analyst's Opinion

Consensus Rating
Bio-Techne has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $476.00, Bio-Techne has a forecasted upside of 29.7% from its current price of $367.10.
Amount of Analyst Coverage
Bio-Techne has only been the subject of 1 research reports in the past 90 days.

4.3 Community Rank

Outperform Votes
Bio-Techne has received 349 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bio-Techne has received 197 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bio-Techne has received 63.92% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bio-Techne and other stocks. Vote “Outperform” if you believe TECH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.

1.7 Dividend Strength

Dividend Yield
Bio-Techne has a dividend yield of 0.34%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Bio-Techne does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Bio-Techne is 29.56%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 15.92% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bio-Techne insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,288,528.00 in company stock.
Percentage Held by Insiders
Only 4.10% of the stock of Bio-Techne is held by insiders.
Percentage Held by Institutions
92.57% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Bio-Techne are expected to grow by 17.54% in the coming year, from $6.84 to $8.04 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bio-Techne is 84.78, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.35.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bio-Techne is 84.78, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 16.89.
Price to Earnings Growth Ratio
Bio-Techne has a PEG Ratio of 2.72. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Bio-Techne has a P/B Ratio of 9.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

Is Bio-Techne a buy right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bio-Techne stock.
View analyst ratings for Bio-Techne or view top-rated stocks.
How has Bio-Techne's stock been impacted by COVID-19?: Bio-Techne's stock was trading at $180.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TECH shares have increased by 103.3% and is now trading at $367.10.
View which stocks have been most impacted by COVID-19.
When is Bio-Techne's next earnings date?: Bio-Techne is scheduled to release its next quarterly earnings announcement on Tuesday, February 1st 2022.
View our earnings forecast for Bio-Techne.
How can I listen to Bio-Techne's earnings call?: Bio-Techne will be holding an earnings conference call on Tuesday, February 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13726340".
How were Bio-Techne's earnings last quarter?: Bio-Techne Co. (NASDAQ:TECH) announced its quarterly earnings results on Monday, November, 1st. The biotechnology company reported $1.83 earnings per share for the quarter, topping analysts' consensus estimates of $1.72 by $0.11. The biotechnology company had revenue of $257.72 million for the quarter, compared to analysts' expectations of $254.37 million. Bio-Techne had a trailing twelve-month return on equity of 15.86% and a net margin of 17.94%. During the same period last year, the firm posted $1.15 EPS.
View Bio-Techne's earnings history.
How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?: Bio-Techne declared a quarterly dividend on Wednesday, November 3rd. Shareholders of record on Friday, November 12th will be paid a dividend of $0.32 per share on Friday, November 26th. This represents a $1.28 annualized dividend and a yield of 0.35%. The ex-dividend date is Wednesday, November 10th.
View Bio-Techne's dividend history.
Is Bio-Techne a good dividend stock?: Bio-Techne pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.34%. The dividend payout ratio of Bio-Techne is 29.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 15.92% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.
View Bio-Techne's dividend history.
What price target have analysts set for TECH?: 8 brokers have issued 1-year target prices for Bio-Techne's shares. Their forecasts range from $400.00 to $548.00. On average, they expect Bio-Techne's stock price to reach $476.00 in the next year. This suggests a possible upside of 29.7% from the stock's current price.
View analysts' price targets for Bio-Techne or view top-rated stocks among Wall Street analysts.
Who are Bio-Techne's key executives?: Bio-Techne's management team includes the following people:
Charles R. Kummeth, President, Chief Executive Officer & Director (LinkedIn Profile)
James T. Hippel, CFO & Principal Accounting Officer (LinkedIn Profile)
Robert Monroe, Chief Medical Officer
Brenda Swierenga Furlow, Secretary & Chief Compliance Officer
Robert M. Gavin, Vice President-Corporate Development
What is Charles Kummeth's approval rating as Bio-Techne's CEO?: 95 employees have rated Bio-Techne CEO Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among Bio-Techne's employees.
Who are some of Bio-Techne's key competitors?: Some companies that are related to Bio-Techne include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), PerkinElmer (PKI), Waters (WAT), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Harvard Bioscience (HBIO), Fluidigm (FLDM), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of TECH's competitors.
What other stocks do shareholders of Bio-Techne own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).
What is Bio-Techne's stock symbol?: Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."
Who are Bio-Techne's major shareholders?: Bio-Techne's stock is owned by a variety of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (0.60%), Conestoga Capital Advisors LLC (0.16%), Russell Investments Group Ltd. (0.11%), State of Alaska Department of Revenue (0.05%), Leavell Investment Management Inc. (0.05%) and Retirement Systems of Alabama (0.03%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne.
Which major investors are selling Bio-Techne stock?: TECH stock was sold by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, Crossmark Global Holdings Inc., Patton Fund Management Inc., Parallel Advisors LLC, Tributary Capital Management LLC, IBM Retirement Fund, Leavell Investment Management Inc., and Retirement Systems of Alabama. Company insiders that have sold Bio-Techne company stock in the last year include Brenda S Furlow, Charles R Kummeth, Glenn Hedde, James Hippel, Kim Kelderman, Norman David Eansor, and Roeland Nusse.
View insider buying and selling activity for Bio-Techne or view top insider-selling stocks.
Which major investors are buying Bio-Techne stock?: TECH stock was purchased by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Segantii Capital Management Ltd, Royal London Asset Management Ltd., Russell Investments Group Ltd., State of Alaska Department of Revenue, Wealthfront Advisers LLC, Radnor Capital Management LLC, and Agate Pass Investment Management LLC.
View insider buying and selling activity for Bio-Techne or or view top insider-buying stocks.
How do I buy shares of Bio-Techne?: Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Bio-Techne's stock price today?: One share of TECH stock can currently be purchased for approximately $367.10.
How much money does Bio-Techne make?: Bio-Techne has a market capitalization of $14.43 billion and generates $931.03 million in revenue each year. The biotechnology company earns $140.41 million in net income (profit) each year or $4.33 on an earnings per share basis.
How many employees does Bio-Techne have?: Bio-Techne employs 2,600 workers across the globe.
Does Bio-Techne have any subsidiaries?: The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
When was Bio-Techne founded?: Bio-Techne was founded in 1981.
What is Bio-Techne's official website?: The official website for Bio-Techne is www.bio-techne.com.
Where are Bio-Techne's headquarters?: Bio-Techne is headquartered at 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413.
How can I contact Bio-Techne?: Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at (612) 379-8854, via email at [email protected], or via fax at 612-656-4400.

This page was last updated on 1/23/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Bio-Techne Stock Forecast, Price & News

About Bio-Techne

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Company Calendar

Social Links

MarketRank™

Overall MarketRank™

3.4 Analyst's Opinion

4.3 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

1.7 Dividend Strength

2.5 Company Ownership

1.9 Earnings and Valuation

Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

Is Bio-Techne a buy right now?

How has Bio-Techne's stock been impacted by COVID-19?

When is Bio-Techne's next earnings date?

How can I listen to Bio-Techne's earnings call?

How were Bio-Techne's earnings last quarter?

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Is Bio-Techne a good dividend stock?

What price target have analysts set for TECH?

Who are Bio-Techne's key executives?

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

Who are some of Bio-Techne's key competitors?

What other stocks do shareholders of Bio-Techne own?

What is Bio-Techne's stock symbol?

Who are Bio-Techne's major shareholders?

Which major investors are selling Bio-Techne stock?

Which major investors are buying Bio-Techne stock?

How do I buy shares of Bio-Techne?

What is Bio-Techne's stock price today?

How much money does Bio-Techne make?

How many employees does Bio-Techne have?

Does Bio-Techne have any subsidiaries?

When was Bio-Techne founded?

What is Bio-Techne's official website?

Where are Bio-Techne's headquarters?

How can I contact Bio-Techne?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™